Black Diamond Therapeutics (BDTX) Competitors $2.87 -0.01 (-0.35%) Closing price 04:00 PM EasternExtended Trading$2.88 +0.00 (+0.17%) As of 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BDTX vs. KURA, SIGA, BCAX, VIR, RLAY, KROS, MGTX, MRVI, TYRA, and ORGOShould you be buying Black Diamond Therapeutics stock or one of its competitors? The main competitors of Black Diamond Therapeutics include Kura Oncology (KURA), Siga Technologies (SIGA), Bicara Therapeutics (BCAX), Vir Biotechnology (VIR), Relay Therapeutics (RLAY), Keros Therapeutics (KROS), MeiraGTx (MGTX), Maravai LifeSciences (MRVI), Tyra Biosciences (TYRA), and Organogenesis (ORGO). These companies are all part of the "pharmaceutical products" industry. Black Diamond Therapeutics vs. Its Competitors Kura Oncology Siga Technologies Bicara Therapeutics Vir Biotechnology Relay Therapeutics Keros Therapeutics MeiraGTx Maravai LifeSciences Tyra Biosciences Organogenesis Black Diamond Therapeutics (NASDAQ:BDTX) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment. Does the media favor BDTX or KURA? In the previous week, Kura Oncology had 8 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 11 mentions for Kura Oncology and 3 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.57 beat Kura Oncology's score of 1.30 indicating that Black Diamond Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Diamond Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Kura Oncology 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend BDTX or KURA? Black Diamond Therapeutics presently has a consensus target price of $11.67, indicating a potential upside of 306.50%. Kura Oncology has a consensus target price of $24.10, indicating a potential upside of 196.43%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Black Diamond Therapeutics is more favorable than Kura Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Diamond Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Kura Oncology 0 Sell rating(s) 4 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.80 Which has more risk & volatility, BDTX or KURA? Black Diamond Therapeutics has a beta of 2.93, indicating that its stock price is 193% more volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500. Do insiders and institutionals believe in BDTX or KURA? 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 6.0% of Black Diamond Therapeutics shares are owned by company insiders. Comparatively, 6.4% of Kura Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is BDTX or KURA more profitable? Black Diamond Therapeutics' return on equity of 12.70% beat Kura Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Black Diamond TherapeuticsN/A 12.70% 9.58% Kura Oncology N/A -52.32%-29.59% Which has stronger earnings and valuation, BDTX or KURA? Black Diamond Therapeutics has higher earnings, but lower revenue than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlack Diamond TherapeuticsN/AN/A-$69.68M$0.2312.48Kura Oncology$53.88M13.10-$173.98M-$2.26-3.60 SummaryBlack Diamond Therapeutics beats Kura Oncology on 10 of the 14 factors compared between the two stocks. Get Black Diamond Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BDTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BDTX vs. The Competition Export to ExcelMetricBlack Diamond TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$163.97M$3.13B$5.76B$9.85BDividend YieldN/A2.28%6.71%4.51%P/E Ratio12.487.5859.1122.53Price / SalesN/A458.96547.00119.09Price / CashN/A44.5237.0558.92Price / Book1.959.9310.916.06Net Income-$69.68M-$53.38M$3.29B$266.28M7 Day Performance0.70%0.05%0.01%-0.76%1 Month Performance1.41%7.08%7.06%3.83%1 Year Performance-48.93%11.92%50.09%24.39% Black Diamond Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BDTXBlack Diamond Therapeutics3.2968 of 5 stars$2.87-0.3%$11.67+306.5%-50.1%$163.97MN/A12.4890News CoveragePositive NewsAnalyst ForecastKURAKura Oncology3.8395 of 5 stars$7.65flat$24.10+215.0%-58.3%$664M$53.88M-3.38130News CoveragePositive NewsAnalyst ForecastSIGASiga Technologies2.4062 of 5 stars$8.70-4.7%N/A+11.5%$653.76M$138.72M8.0840News CoveragePositive NewsOptions VolumeBCAXBicara Therapeutics2.3786 of 5 stars$11.32-4.4%$32.25+184.9%N/A$646.02MN/A0.0032Positive NewsVIRVir Biotechnology3.2145 of 5 stars$4.38-4.4%$30.25+590.6%-29.2%$636.24M$74.21M-1.10580News CoverageAnalyst ForecastInsider TradeRLAYRelay Therapeutics2.3956 of 5 stars$3.51-4.9%$17.25+391.5%-36.5%$636.20M$10.01M0.00330News CoverageAnalyst ForecastKROSKeros Therapeutics3.3648 of 5 stars$14.76-5.1%$30.00+103.3%-67.0%$631.98M$3.55M50.19100News CoveragePositive NewsMGTXMeiraGTx4.5065 of 5 stars$7.58-3.2%$24.00+216.6%+87.5%$629.90M$33.28M-3.72300News CoveragePositive NewsGap UpMRVIMaravai LifeSciences3.7785 of 5 stars$2.40-2.0%$5.75+139.6%-73.0%$625.64M$259.18M-1.76610Positive NewsOptions VolumeTYRATyra Biosciences2.7712 of 5 stars$12.00+2.5%$30.83+156.9%-42.5%$624.11MN/A0.0020News CoveragePositive NewsAnalyst ForecastORGOOrganogenesis4.2365 of 5 stars$4.67-4.5%$7.50+60.6%+81.7%$620.33M$482.04M0.00950Positive News Related Companies and Tools Related Companies KURA Competitors SIGA Competitors BCAX Competitors VIR Competitors RLAY Competitors KROS Competitors MGTX Competitors MRVI Competitors TYRA Competitors ORGO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BDTX) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Black Diamond Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Black Diamond Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
